Siegfried Reich, Ph.D., serves as executive vice president and chief scientific officer (CSO) of Turning Point Therapeutics. Dr. Reich has over 25 years of pharmaceutical and biotech experience developing more than 20 drug candidates, including the approved drugs Viracept® for HIV and the tyrosine kinase inhibitor Inlyta® for the treatment of kidney cancer.
Prior to joining Turning Point Therapeutics, Dr. Reich was senior vice president of research and co-founder of eFFECTOR Therapeutics where he led discovery of three first-in-class small-molecule inhibitors, of MNK (tomivosertib), eIF4A (zotatifin), and eukaryotic initiation factor 4E (eIF4E). eIF4E, in development under a collaboration with Pfizer, is an oncogenic driver located downstream from both the RAS and PI3K signaling pathways that is linked to poor prognosis and resistance to certain cancer therapies.
Prior to eFFECTOR, Dr. Reich was a research fellow at the Lilly Biotech Center in San Diego, where he led fragment-based and structure-based design efforts across the Lilly discovery portfolio. Previously he was vice president and head of drug discovery at SGX; vice president and head of viral and ophthalmic diseases at Pfizer; and director and head of medicinal chemistry at Agouron. Dr. Reich is a coinventor of two marketed products, the TKI Inlyta® (axitinib) and protease inhibitor Viracept® (nelfinavir), and a coinventor of numerous candidates currently in clinical development. Dr. Reich is also a past recipient of the PhRMA Discoverers Award for the discovery of Viracept®.
Dr. Reich serves as a scientific advisor to eFFECTOR Therapeutics. He completed his post-doctoral training in chemistry at the University of California, Berkeley and his Ph.D. in Chemistry at the University of California, Irvine. He received his B.S. in Chemistry from San Diego State University.